Reviewing BioLineRx Ltd. (BLRX)’s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s results – CryptoCoinsTribune

This is a contrast between BioLineRx Ltd. (NASDAQ:BLRX) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents BioLineRx Ltd. (NASDAQ:BLRX) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)s net margins, return on equity and return on assets.

Analyst Recommendations

The table given features the ratings and recommendations for BioLineRx Ltd. and Dicerna Pharmaceuticals Inc.

Meanwhile, Dicerna Pharmaceuticals Inc.s average price target is $22, while its potential upside is 51.52%.

Insider & Institutional Ownership

BioLineRx Ltd. and Dicerna Pharmaceuticals Inc. has shares owned by institutional investors as follows: 27.13% and 90%. Insiders owned roughly 3.46% of BioLineRx Ltd.s shares. Comparatively, 8.38% are Dicerna Pharmaceuticals Inc.s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year BioLineRx Ltd. had bearish trend while Dicerna Pharmaceuticals Inc. had bullish trend.

Summary

Dicerna Pharmaceuticals Inc. beats BioLineRx Ltd. on 6 of the 8 factors.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companys preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post here:

Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune